A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT2527, a CDK9 Inhibitor in Adult Patients With Advanced Solid Tumors

Disclosures

• J.T. Henry: Travel expenses (Sarah Canon Research Institute); stock or stock options (HCA); other financial or non-financial interests (Abbiscko Therapeutics, ABl Bio,  Accutar Biotech, ADC Therapeutics, Agenus, Aileron Therapeutics, Amgen, Artios, AstraZenaca, Bicycle Therapeutics, BioAlta, BioInvent pharma, Biosplice Therapeutics, Black Diamond Therapeutics, Boehringer Ingelheim, Cyteir, Daiichi Sankyo, Eli Lilly, Epizyme, Erasca, Exelixis, FujiFilm, GSK, Hutchison MediPharma, ICON PLC, IGM Biosciences, Immunitas Therapeutics, Immunogen, Jazz Pharmaceuticals, Jacobio pharmaceuticals, Jounce Pharma, Jubilant Therapeutics, Loxo Oncology, Merck, Metabomed, Mirati, Molecular Templates, Navire Pharma, Nikang Pharmaceuticals, Oncorus, Prelude Therapeutics, Poseida, PureTech, Pyramid, Rascal Therapeutics, Regeneron, Relay Therapeutics, Rgenix Inc, Ribon Therapeutics, Sapience, Sarah Cannon Development Innovations, Sarah Cannon Research Institute, Seagen, Simcha Therapeutics, Siranomics, Stingthera, Synthorx Inc, Takeda, Tallac Therapeutics, Tarveda, Teneothree, Tesaro, Turning Point Pharma, Xencor)
• D. Orr: No conflicts of interest to disclose
• A. Basu-Mallick: Research funding (Prelude Therapeutics)
• A. Spira: Leadership (NEXT Oncology Virginia); stock and other ownership interests (Eli Lilly); honoraria (Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, CytomX Therapeutics, Janssen, MedImmune, Merck, Novartis, Takeda); consulting or advisory role (Amgen, Array BioPharma, AstraZeneca, Black Diamond Therapeutics, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo, Gritstone Bio, Gritstone Oncology, Incyte, Janssen, Jazz Pharmaceuticals, Lilly, MedImmune, Merck, Mersana, Mirati Therapeutics, Regeneron, Novartis, Takeda); research funding (AbbVie, ADCT, Alkermes, Amgen, Astellas Pharma, Arch Therapeutics, Astex Pharmaceuticals, AstraZeneca, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, CytomX Therapeutics, Daiichi Sankyo, Gritstone, Ignyta, Incyte, Janssen, LAM Therapeutics, Loxo, Macrogenics, MedImmune, Mersana, Mirati Therapeutics, Newlink Genetics, Novartis, Plexxikon, Regeneron, Revolution Medicines, Roche, Rubius, Synthekine, Takeda, Trovagene)
• M.R. Patel: Advisory role (Olema Pharmaceuticals); leadership (ION Pharma); honoraria (Janssen); and research funding (Accutar Biotech, Acerta Pharma, Adagene, ADC Therapeutics, Agenus, Aileron Therapeutics, Artios, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, BioNTech AG, BioTheryX, Black Diamond Therapeutics, Blueprint Pharmaceuticals, Boehringer Ingelheim, Celgene, CicloMed, Clovis Oncology, Compugen, Cullinan Oncology, Cyteir Therapeutics, Daiichi Sankyo, Eli Lilly, Erasca, Inc, Evelo Therapeutics, Genetech/Roche, Gilead Sciences, GSK, H3 Biomedicine, Hengrui Therapeutics, Hutchison MediPharma, IGM Biosciences, Immune-Onc Therapeutics, Immunogen, Jacobio, Janssen, Jazz Pharmaceuticals, Klus Pharma, Kymab, Loxo, LSK Biopartners, Lycera, MabSpace Biosciences, Macrogenics, Merck, Millennium, Mirati Therapeutics, Moderna Therapeutics, NGM Biopharmaceuticals, Novartis, Nurix, Olema, ORIC Pharmaceuticals, Pfizer, Pionyr, Prelude Therapeutics, Puretech, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Samumed, Seven and Eight Biopharmaceuticals, Silicon Therapeutics, Step Pharma, Syndax, Synthorx, Taiho Pharmaceutical, TeneoBio, Tesaro, TopAlliance BioSciences Inc., Treadwell Therapeutics, Vigeo, Xencor, Zymeworks)
• C. Lihou, W. Sun, N. Sharma, P. Scherle, and R. Chiaverelli: Employees of Prelude Therapeutics Inc., Wilmington, DE and may own stocks or shares